Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment

Cells. 2023 Nov 10;12(22):2600. doi: 10.3390/cells12222600.

Abstract

This review on acne transcriptomics allows for deeper insights into the pathogenesis of acne and isotretinoin's mode of action. Puberty-induced insulin-like growth factor 1 (IGF-1), insulin and androgen signaling activate the kinase AKT and mechanistic target of rapamycin complex 1 (mTORC1). A Western diet (hyperglycemic carbohydrates and milk/dairy products) also co-stimulates AKT/mTORC1 signaling. The AKT-mediated phosphorylation of nuclear FoxO1 and FoxO3 results in their extrusion into the cytoplasm, a critical switch which enhances the transactivation of lipogenic and proinflammatory transcription factors, including androgen receptor (AR), sterol regulatory element-binding transcription factor 1 (SREBF1), peroxisome proliferator-activated receptor γ (PPARγ) and signal transducer and activator of transcription 3 (STAT3), but reduces the FoxO1-dependent expression of GATA binding protein 6 (GATA6), the key transcription factor for infundibular keratinocyte homeostasis. The AKT-mediated phosphorylation of the p53-binding protein MDM2 promotes the degradation of p53. In contrast, isotretinoin enhances the expression of p53, FoxO1 and FoxO3 in the sebaceous glands of acne patients. The overexpression of these proapoptotic transcription factors explains isotretinoin's desirable sebum-suppressive effect via the induction of sebocyte apoptosis and the depletion of BLIMP1(+) sebocyte progenitor cells; it also explains its adverse effects, including teratogenicity (neural crest cell apoptosis), a reduced ovarian reserve (granulosa cell apoptosis), the risk of depression (the apoptosis of hypothalamic neurons), VLDL hyperlipidemia, intracranial hypertension and dry skin.

Keywords: FoxO1; FoxO3; acne; apoptosis; isotretinoin; mTORC1; p53; pathogenesis; therapy; transcriptomics.

Publication types

  • Review

MeSH terms

  • Acne Vulgaris* / drug therapy
  • Acne Vulgaris* / genetics
  • Humans
  • Isotretinoin* / metabolism
  • Isotretinoin* / pharmacology
  • Isotretinoin* / therapeutic use
  • Mechanistic Target of Rapamycin Complex 1 / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Transcription Factors / metabolism
  • Transcriptome / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Isotretinoin
  • Proto-Oncogene Proteins c-akt
  • Tumor Suppressor Protein p53
  • Mechanistic Target of Rapamycin Complex 1
  • Transcription Factors

Grants and funding

This research received no external funding.